binding domain binds human APLP2 with a KD of about 800 nM to about 1 μM, as measured by surface plasmon resonance, or equivalent assay.

40. The anti-APLP2 antibody or antigen-binding fragment of claim **38**, wherein the reference antibody comprises an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:26/10, 34/10, and 42/10.

41. The anti-APLP2 antibody or antigen-binding fragment of claim **38**, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human APLP2 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 2.

42. An antibody-drug conjugate (ADC) comprising the anti-APLP2 antibody or antigen-binding fragment of claim **38** and a cytotoxic agent, wherein the bispecific antigen-binding molecule and the cytotoxic agent are covalently attached via a linker

43. A pharmaceutical composition comprising the bispecific antigen-binding molecule of 1-36, the isolated anti-APLP2 antibody or antigen-binding fragment thereof of claim **38** and a pharmaceutically acceptable carrier or diluent.

44. A method for treating a cancer in a subject, the method comprising administering to the subject the pharmaceutical composition of claim **43**.

45. The method of claim **44**, wherein the cancer is selected from the group consisting of prostate cancer, bladder cancer, cervical cancer, lung cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, stomach cancer, uterine cancer, and ovarian cancer.

46. The method of claim **45**, wherein the cancer is breast cancer, optionally an IHC2+ breast cancer.

47. Use of the pharmaceutical composition of claim **43** in the treatment of a disease or disorder associated with expression of HER2.

48. The use of claim **47**, wherein the disease or disorder is cancer.

49. Use of the bispecific antigen-binding molecule of **1-36**, the isolated anti-APLP2 antibody or antigen-binding fragment thereof of claim **38**, for the manufacture of a medicament for use in the treatment of cancer, optionally wherein the cancer is breast cancer.

* * * * *